Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Change in Inventory (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Change in Inventory data on record, last reported at -$47000.0 in Q3 2025.

  • For Q3 2025, Change in Inventory rose 95.93% year-over-year to -$47000.0; the TTM value through Sep 2025 reached -$1.1 million, down 116.23%, while the annual FY2024 figure was -$1.3 million, 21966.67% down from the prior year.
  • Change in Inventory reached -$47000.0 in Q3 2025 per BTAI's latest filing, up from -$136000.0 in the prior quarter.
  • Across five years, Change in Inventory topped out at $713000.0 in Q2 2022 and bottomed at -$1.2 million in Q3 2024.
  • Average Change in Inventory over 4 years is $30600.0, with a median of -$27000.0 recorded in 2023.
  • The widest YoY moves for Change in Inventory: up 1457.58% in 2024, down 3033.33% in 2024.
  • A 4-year view of Change in Inventory shows it stood at $577000.0 in 2022, then tumbled by 104.68% to -$27000.0 in 2023, then tumbled by 3033.33% to -$846000.0 in 2024, then skyrocketed by 94.44% to -$47000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Inventory were -$47000.0 in Q3 2025, -$136000.0 in Q2 2025, and -$37000.0 in Q1 2025.